Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Two large deals and an acquisition, all totaling about $4.64 billion, are helping close out a strong year. Yarrow Bioscience Inc. cut a potentially $1.36 billion deal with Shanghai Scizeng Medical ...

In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.

Kymera Therapeutics, Inc. KYMR recently announced that the FDA granted Fast Track designation to pipeline candidate KT-621 ...

Objective To evaluate whether a point-of-care decision rule could safely reduce antibiotic prescriptions in children ...

In this video, Gailen D. Marshall Jr., MD, PhD, chair of allergy and immunology at University of Mississippi Medical Center, discusses the clinical development of the nanobody compound lunsekimig for ...

Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...

Shares of biotechnology firm MacroGenics are under significant pressure following reports that confirmatory clinical trials ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated ...

Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...

Investing.com -- Sanofi (EURONEXT:SAN) said Wednesday that its investigational therapy efdoralprin alfa has received orphan ...